Skip to content

Efalizumab reduced PASI progression

A reduced first-order PASI response model with a fixed treatment-associated asymptote and response half-time.

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model ↗

Frontiers in Immunology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the two empirical PASI progression presets differ over time?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Gottlieb escalating-dose PASI progression probe

Reduced PASI progression under fixed treated-response parameters; the cohort label identifies context only.

0–1,344 hour

Scenario details

Gottlieb escalating-dose PASI progression probe

Reduced PASI progression under fixed treated-response parameters; the cohort label identifies context only.

Readouts

PASI score · dimensionless
PASI score over the selected simulation window.
PASI change · 1/hour
Instantaneous signed PASI change; negative values indicate decline.
PASI gap to steady state · dimensionless
Current PASI minus the selected asymptotic PASI.

Study purpose

  • How do the model's key biological readouts change under gottlieb escalating-dose pasi progression probe?

Assumptions

  • Reduced PASI relaxation with a fixed response coefficient and a fixed asymptotic PASI value in each condition.
  • The elapsed-hour state is a nonfeedback clock. The model has no antibody PK, administered-dose mapping or FcRn compartments.
  • Two conditions use reported response parameters; two use authored exploratory effective parameters, not reported paper estimates or a reproduced optimizer.
  • Each initial PASI is fixed by the selected condition. No patient fit, population simulation or clinical efficacy or safety prediction is provided.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
1344 → 168

Time between reported samples.

h
24 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

A reduced first-order PASI response model with a fixed treatment-associated asymptote and response half-time.

A reduced first-order PASI response model with a fixed treatment-associated asymptote and response half-time.

Model details

2 parameters · 2 states · 2 equations · 8 derived outputs

Classification & API access
Therapeutic
Efalizumab
Modality
Monoclonal antibody
Target
ITGAL, CD11a, LFA-1 alpha
Disease / scope
Plaque psoriasis
ParameterDefaultUnitDescription
Effect equilibration timeTp_h397hEffect equilibration time coefficient used by the released system of model equations.
Steady-state PASI scoreYss_current_PASI14.8—Steady-state PASI score coefficient used by the released system of model equations.

Related models

Certolizumab pegol subcutaneous PKNivolumab exposure and tumor-size dynamicsBevacizumab and VEGF165 conditional QSS bindingMepolizumab exposure and blood eosinophils

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics